PE20212307A1 - Vectores de orthopoxvirus modificados - Google Patents

Vectores de orthopoxvirus modificados

Info

Publication number
PE20212307A1
PE20212307A1 PE2021000922A PE2021000922A PE20212307A1 PE 20212307 A1 PE20212307 A1 PE 20212307A1 PE 2021000922 A PE2021000922 A PE 2021000922A PE 2021000922 A PE2021000922 A PE 2021000922A PE 20212307 A1 PE20212307 A1 PE 20212307A1
Authority
PE
Peru
Prior art keywords
modified orthopoxvirus
vectors
orthopoxvirus vectors
modified
adaptability
Prior art date
Application number
PE2021000922A
Other languages
English (en)
Inventor
John C Bell
Michael S Huh
Matthew Y Tang
Adrian Pelin
Caroline J Breitbach
Michael F Burgess
Steven H Bernstein
Original Assignee
Ottawa Hospital Res Inst
Turnstone Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Hospital Res Inst, Turnstone Biologics Corp filed Critical Ottawa Hospital Res Inst
Publication of PE20212307A1 publication Critical patent/PE20212307A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La solicitud se refiere a vectores de orthopoxvirus modificados, asi como a metodos para utilizar los mismos para el tratamiento de diversos canceres. La solicitud provee vectores de orthopoxvirus modificados que exhiben varias actividades terapeuticas beneficiosas, incluyendo aumentadas actividad oncolitica, dispersion de la infeccion, evasion inmune, persistencia tumoral, capacidad de incorporacion de secuencias de ADN exogenas, adaptabilidad para fabricacion a gran escala y seguridad
PE2021000922A 2018-12-21 2019-12-20 Vectores de orthopoxvirus modificados PE20212307A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862784372P 2018-12-21 2018-12-21
US201962872699P 2019-07-10 2019-07-10
US201962930524P 2019-11-04 2019-11-04
PCT/CA2019/051898 WO2020124273A1 (en) 2018-12-21 2019-12-20 Modified orthopoxvirus vectors

Publications (1)

Publication Number Publication Date
PE20212307A1 true PE20212307A1 (es) 2021-12-10

Family

ID=71100021

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000922A PE20212307A1 (es) 2018-12-21 2019-12-20 Vectores de orthopoxvirus modificados

Country Status (18)

Country Link
US (2) US20220380799A1 (es)
EP (2) EP3898998A4 (es)
JP (2) JP2022514420A (es)
KR (2) KR20210132002A (es)
CN (2) CN113454231A (es)
AU (2) AU2019404639A1 (es)
BR (2) BR112021011730A2 (es)
CA (2) CA3124301A1 (es)
CL (1) CL2021001646A1 (es)
CO (1) CO2021009354A2 (es)
EC (1) ECSP21053474A (es)
IL (2) IL284180A (es)
MX (2) MX2021007438A (es)
PE (1) PE20212307A1 (es)
PH (1) PH12021551436A1 (es)
SG (1) SG11202106460XA (es)
TW (1) TW202039851A (es)
WO (2) WO2020124274A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200121297A (ko) 2018-01-05 2020-10-23 오타와 하스피털 리서치 인스티튜트 변형된 오르토폭스바이러스 벡터
WO2021102307A1 (en) * 2019-11-20 2021-05-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccinia viruses and methods for using vaccinia viruses
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도
WO2023135313A1 (en) * 2022-01-17 2023-07-20 Nouscom Ag Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment
WO2023238106A1 (en) * 2022-06-10 2023-12-14 Transgene Recombinant virus expressing interleukin-12
WO2024023740A1 (en) * 2022-07-27 2024-02-01 Astrazeneca Ab Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269619A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
AU2003290528A1 (en) * 2002-10-15 2004-05-04 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods and reagents for inducing immunity
CA2705869C (en) * 2007-11-19 2012-10-30 Philippe Erbs Poxviral oncolytic vectors
PE20160673A1 (es) * 2013-08-22 2016-07-21 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Terapias inmuno-oncoliticas
RU2696312C2 (ru) * 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
KR20200121297A (ko) * 2018-01-05 2020-10-23 오타와 하스피털 리서치 인스티튜트 변형된 오르토폭스바이러스 벡터

Also Published As

Publication number Publication date
IL284180A (en) 2021-08-31
MX2021007439A (es) 2021-08-05
CA3124301A1 (en) 2020-06-25
CA3124287A1 (en) 2020-06-25
WO2020124273A1 (en) 2020-06-25
MX2021007438A (es) 2021-09-21
JP2022514420A (ja) 2022-02-10
CL2021001646A1 (es) 2022-02-18
EP3898998A4 (en) 2022-10-05
BR112021011730A2 (pt) 2021-08-31
SG11202106460XA (en) 2021-07-29
BR112021012078A2 (pt) 2021-08-31
KR20210132003A (ko) 2021-11-03
IL284188A (en) 2021-08-31
US20220056480A1 (en) 2022-02-24
WO2020124274A1 (en) 2020-06-25
EP3898998A1 (en) 2021-10-27
EP3898997A4 (en) 2022-11-16
CN113661246A (zh) 2021-11-16
ECSP21053474A (es) 2021-11-18
AU2019410148A1 (en) 2021-08-12
PH12021551436A1 (en) 2021-12-06
JP2022516006A (ja) 2022-02-24
KR20210132002A (ko) 2021-11-03
EP3898997A1 (en) 2021-10-27
TW202039851A (zh) 2020-11-01
US20220380799A1 (en) 2022-12-01
CO2021009354A2 (es) 2021-11-19
CN113454231A (zh) 2021-09-28
AU2019404639A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
PE20212307A1 (es) Vectores de orthopoxvirus modificados
MX2020007011A (es) Vectores de vaccinia modificados.
GT201700200A (es) Composiciones y métodos para activar la señalización dependiente del "estimulador del gen de interferon"
MX2020007010A (es) Vectores modificados de orthopoxvirus.
PE20191842A1 (es) Vectores de neoantigeno de alfavirus
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
CL2021000216A1 (es) Compuestos 1h-pyrazolo [4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y métodos y usos de los mismos
MX2018008266A (es) Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer.
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
UY37563A (es) Aislados de bacillus y usos de los mismos
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR122021000068A8 (pt) Composições e usos em métodos para estimular a eficácia de imunoterapia celular adotiva
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
EA201991214A1 (ru) Антитела против pd-1 и их композиции
EP3828267A3 (en) Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
MX2018004600A (es) Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
MX2020001637A (es) Agentes de union a cd96 como inmunomoduladores.
BR112017021700A2 (pt) composições terapêuticas e métodos de uso para o tratamento do câncer
WO2015170158A8 (en) Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation
CO6290694A2 (es) Paramyxovirus eficaz como antitumoral
AR117470A1 (es) Vectores de orthopoxvirus modificados
MX2019006337A (es) Métodos para el tratamiento de una enfermedad poliquística renal.
EA202091645A1 (ru) Модифицированные ортопоксвирусные векторы
WO2015048523A3 (en) Mutant chondroitinase abc i compositions and methods of their use